CN1254237C - 透明水性麻醉组合物 - Google Patents

透明水性麻醉组合物 Download PDF

Info

Publication number
CN1254237C
CN1254237C CNB008198292A CN00819829A CN1254237C CN 1254237 C CN1254237 C CN 1254237C CN B008198292 A CNB008198292 A CN B008198292A CN 00819829 A CN00819829 A CN 00819829A CN 1254237 C CN1254237 C CN 1254237C
Authority
CN
China
Prior art keywords
propofol
autoclaving
pharmaceutical composition
clear aqueous
aqueous pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008198292A
Other languages
English (en)
Chinese (zh)
Other versions
CN1454085A (zh
Inventor
S·佩
S·里范卡
S·科查雷卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bharat Serums and Vaccines Ltd
Original Assignee
Bharat Serums and Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums and Vaccines Ltd filed Critical Bharat Serums and Vaccines Ltd
Publication of CN1454085A publication Critical patent/CN1454085A/zh
Application granted granted Critical
Publication of CN1254237C publication Critical patent/CN1254237C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008198292A 2000-06-21 2000-12-14 透明水性麻醉组合物 Expired - Fee Related CN1254237C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN573MU2000 IN187686B (2) 2000-06-21 2000-06-21
IN573/MUM/2000 2000-06-21

Publications (2)

Publication Number Publication Date
CN1454085A CN1454085A (zh) 2003-11-05
CN1254237C true CN1254237C (zh) 2006-05-03

Family

ID=11097257

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008198292A Expired - Fee Related CN1254237C (zh) 2000-06-21 2000-12-14 透明水性麻醉组合物

Country Status (26)

Country Link
US (1) US7138387B2 (2)
EP (1) EP1299095B1 (2)
JP (1) JP4907833B2 (2)
KR (1) KR100810066B1 (2)
CN (1) CN1254237C (2)
AP (1) AP2002002674A0 (2)
AT (1) ATE267592T1 (2)
AU (2) AU3597201A (2)
BG (1) BG107463A (2)
BR (1) BR0017268A (2)
CA (1) CA2414064C (2)
DE (1) DE60011149T2 (2)
DK (1) DK1299095T3 (2)
EA (1) EA005589B1 (2)
ES (1) ES2222271T3 (2)
HU (1) HUP0301646A3 (2)
IL (1) IL153387A0 (2)
IN (1) IN187686B (2)
MX (1) MXPA02012611A (2)
NO (1) NO20025999D0 (2)
NZ (1) NZ523643A (2)
PL (1) PL359624A1 (2)
PT (1) PT1299095E (2)
WO (1) WO2001097796A1 (2)
YU (1) YU2703A (2)
ZA (1) ZA200300336B (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188917B (2) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
PL205271B1 (pl) * 2001-12-28 2010-03-31 Mgi Gp Kompozycja farmaceutyczna rozpuszczalnego w wodzie proleku propofolu
BR0307518A (pt) * 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
CN100438861C (zh) 2002-07-29 2008-12-03 变换药品公司 含水2,6-二异丙基苯酚药物组合物
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
CN103405405A (zh) * 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
JPWO2005067905A1 (ja) * 2004-01-14 2007-12-27 株式会社大塚製薬工場 プロポフォール含有脂肪乳剤
AU2005283726A1 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
CN101287447B (zh) * 2005-08-12 2012-10-24 印度血清及疫苗有限公司 包含丙泊酚的水性麻醉剂组合物
WO2007128866A2 (en) * 2006-05-09 2007-11-15 Novobion Oy Novel chemical compositions
EP2257605A4 (en) * 2008-03-11 2011-03-09 3M Innovative Properties Co HART COATING COMPOSITION
WO2010148288A2 (en) * 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
CN102597116B (zh) 2009-07-21 2013-12-11 3M创新有限公司 可固化组合物、涂覆底片的方法、以及被涂覆的底片
EP2478033A1 (en) 2009-09-16 2012-07-25 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US9051423B2 (en) 2009-09-16 2015-06-09 3M Innovative Properties Company Fluorinated coating and phototools made therewith
US8268067B2 (en) * 2009-10-06 2012-09-18 3M Innovative Properties Company Perfluoropolyether coating composition for hard surfaces
EP2345427A1 (de) * 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
CN103263404B (zh) * 2012-04-28 2017-12-01 中国人民解放军军事医学科学院放射与辐射医学研究所 一种复合麻醉药物
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
EP3407875A4 (en) * 2016-01-29 2019-09-04 Cuda Anesthetics, LLC AQUEOUS PHARMACEUTICAL FORMULATION WITH PROPOFOL
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition

Also Published As

Publication number Publication date
MXPA02012611A (es) 2004-07-30
DE60011149T2 (de) 2005-07-07
YU2703A (sh) 2006-03-03
AP2002002674A0 (en) 2002-12-31
KR20030023875A (ko) 2003-03-20
AU3597201A (en) 2002-01-02
JP2003535893A (ja) 2003-12-02
WO2001097796A1 (en) 2001-12-27
IN187686B (2) 2002-06-08
KR100810066B1 (ko) 2008-03-05
US7138387B2 (en) 2006-11-21
PL359624A1 (en) 2004-08-23
HUP0301646A2 (hu) 2003-09-29
JP4907833B2 (ja) 2012-04-04
US20040014718A1 (en) 2004-01-22
NZ523643A (en) 2004-05-28
EP1299095A1 (en) 2003-04-09
EA200300047A1 (ru) 2003-06-26
BR0017268A (pt) 2003-05-27
EP1299095B1 (en) 2004-05-26
CA2414064A1 (en) 2001-12-27
ES2222271T3 (es) 2005-02-01
DK1299095T3 (da) 2004-10-11
PT1299095E (pt) 2004-10-29
NO20025999L (no) 2002-12-13
ATE267592T1 (de) 2004-06-15
NO20025999D0 (no) 2002-12-13
IL153387A0 (en) 2003-07-06
HUP0301646A3 (en) 2005-06-28
EA005589B1 (ru) 2005-04-28
AU2001235972B2 (en) 2005-07-21
BG107463A (en) 2003-11-28
CA2414064C (en) 2013-01-08
ZA200300336B (en) 2004-04-08
DE60011149D1 (de) 2004-07-01
CN1454085A (zh) 2003-11-05

Similar Documents

Publication Publication Date Title
CN1254237C (zh) 透明水性麻醉组合物
EP2349340B1 (en) Stable aqueous formulations of water insoluble or poorly soluble drugs
CN1010279B (zh) 含有斯波胍灵活性成分的注射用药物组合物的制备方法
CN1658887A (zh) 新的含阻滞共聚物和蒽环类抗癌剂的固体制剂及其生产方法
AU2001235972A1 (en) Clear aqueous anaesthetic composition
CN1416337A (zh) 麻醉制剂
CN1761485A (zh) 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
CN1329488A (zh) 包含类紫杉醇抗肿瘤剂的稳定注射药物组合物
CN1283235C (zh) 清澈稳定的丙泊酚组合物
CN1248680C (zh) 紫杉醇的可注射组合物
CN1146413C (zh) 以对乙酰氨基酚为基础的注射用药物组合物
CN1655824A (zh) 基于聚氧乙烯蓖麻油的稳定药物制剂及其生产方法
CN1625414A (zh) 药物组合物
CN1482910A (zh) 法莫替丁注射液
CN1748705A (zh) 包含孕酮的新的可注射制剂
CN1694713A (zh) oxazaphosphorine和美司钠的液态稳定组合物
CN1646169A (zh) 用于小动物的可注射兽医合成物
CN1843327A (zh) 一种稳定的含有多种维生素的冻干制剂及其制备方法
CN1146417C (zh) 以奎纽普汀和达尔福普汀为主要成分的稳定药物组合物及其制备
CN1183908C (zh) 一种尼莫地平的注射用药物组合物及其制备方法
CN1927206A (zh) 氯诺昔康注射用组合物及其制备方法
CN1305473C (zh) 含鲁比特康的注射用制剂
JPWO2003099288A1 (ja) 医薬組成物
JPWO2019167979A1 (ja) 保存安定性に優れた医薬組成物
CN101062028A (zh) 一种含紫杉烷类化合物的组合物、其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060503

Termination date: 20161214